Spojené státy - angličtina - NLM (National Library of Medicine)

mylan institutional llc - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon 200 [iu] in 1 ml - miacalcin injection is indicated for the treatment of symptomatic paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. there is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients. miacalcin injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). miacalcin injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. it may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or

Spojené státy - angličtina - NLM (National Library of Medicine)

bryant ranch prepack - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon nasal solution is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause. fracture reduction efficacy has not been demonstrated. calcitonin salmon nasal solution should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). - due to the possible association between malignancy and calcitonin-salmon use, the need for continued therapy should be re-evaluated on a periodic basis [see warnings and precautions (5.4)]. - calcitonin salmon nasal solution has not been shown to increase spinal bone mineral density in early postmenopausal women. hypersensitivity to calcitonin-salmon or any of the excipients. reactions have included anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat [see warnings and precautions (5.1)]. risk summary calcitonin salmon nasal solution is not i

Spojené státy - angličtina - NLM (National Library of Medicine)

par pharmaceutical, inc. - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon injection is indicated for the treatment of symptomatic paget’s disease of bone in patients with moderate to severe disease characterized by polyostotic involvement with elevated serum alkaline phosphatase and urinary hydroxyproline excretion. there is no evidence that the prophylactic use of calcitonin salmon is beneficial in asymptomatic patients. calcitonin salmon injection should be used only in patients who do not respond to alternative treatments or for whom such treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). calcitonin salmon injection is indicated for the early treatment of hypercalcemic emergencies, along with other appropriate agents, when a rapid decrease in serum calcium is required, until more specific treatment of the underlying disease can be accomplished. it may also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furose

Spojené státy - angličtina - NLM (National Library of Medicine)

bryant ranch prepack - calcitonin salmon (unii: 7sfc6u2vi5) (calcitonin salmon - unii:7sfc6u2vi5) - calcitonin salmon (synthetic origin) nasal spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause. fracture reduction efficacy has not been demonstrated. calcitonin salmon (synthetic origin) nasal spray should be reserved for patients for whom alternative treatments are not suitable (e.g., patients for whom other therapies are contraindicated or for patients who are intolerant or unwilling to use other therapies). - due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis [see warnings and precautions (5.4)] . - calcitonin salmon (synthetic origin) nasal spray has not been shown to increase spinal bone mineral density in early postmenopausal women. hypersensitivity to calcitonin salmon or any of the excipients. reactions have included anaphylactic shock, anaphylaxis, bronchospasm, and swelling of the tongue or throat [see warnings and precautions (5.1)] .

Kanada - angličtina - Health Canada

pro doc limitee - calcitonin (salmon synthetic) - solution - 200unit - calcitonin (salmon synthetic) 200unit - parathyroid and antiparathyroid agents

Izrael - angličtina - Ministry of Health

genmedix , israel - calcitonin salmon; calcitonin salmon - solution for injection - calcitonin salmon 100 iu/ml; calcitonin salmon 100 iu/ml - calcitonin (salmon synthetic) - calcitonin (salmon synthetic) - calcitonin is indicated for:• prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures.• for the treatment of paget's disease, only in patients who do not respond to alternative treatments or for whom such treatments are not suitable, for example those with severe renal impairment.• treatment of hypercalcemia of malignancy. calcitonin is indicated for:• prevention of acute bone loss due to sudden immobilisation such as in patients with recent osteoporotic fractures.• for the treatment of paget's disease, only in patients who do not respond to alternative treatments or for whom such treatments are not suitable, for example those with severe renal impairment.• treatment of hypercalcemia of malignancy.

Kanada - angličtina - Health Canada

novartis pharmaceuticals canada inc - calcitonin (salmon synthetic) - spray - 200unit - calcitonin (salmon synthetic) 200unit - parathyroid and antiparathyroid agents

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

essential pharma ltd - calcitonin, salmon - solution for injection/infusion - 100 international unit(s)/millilitre - calcitonin preparations; calcitonin (salmon synthetic)

Kanada - angličtina - Health Canada

apotex inc - calcitonin (salmon synthetic) - liquid - 200unit - calcitonin (salmon synthetic) 200unit - parathyroid and antiparathyroid agents

Kanada - angličtina - Health Canada

sanofi-aventis canada inc - calcitonin (salmon synthetic) - solution - 200unit - calcitonin (salmon synthetic) 200unit - parathyroid and antiparathyroid agents